IR Biosciences Holdings, Inc.
IRBS
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.54% | -15.55% | -25.37% | -34.05% | -39.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.54% | -15.55% | -25.37% | -34.05% | -39.18% |
| Operating Income | 8.54% | 15.55% | 25.37% | 34.05% | 39.18% |
| Income Before Tax | 18.27% | 52.57% | 43.54% | -13.72% | -11.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.33% | 52.61% | 43.54% | -13.72% | -11.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.33% | 52.61% | 43.54% | -13.72% | -11.29% |
| EBIT | 8.54% | 15.55% | 25.37% | 34.05% | 39.18% |
| EBITDA | 8.40% | 15.45% | 24.84% | 32.93% | 38.31% |
| EPS Basic | 27.92% | 57.97% | 46.09% | -4.04% | -0.94% |
| Normalized Basic EPS | 27.25% | 23.01% | 20.26% | 17.01% | 15.02% |
| EPS Diluted | 27.92% | 57.97% | 46.09% | -4.04% | -0.94% |
| Normalized Diluted EPS | 27.25% | 23.01% | 20.26% | 17.01% | 15.02% |
| Average Basic Shares Outstanding | 19.73% | 15.13% | 10.82% | 9.69% | 11.49% |
| Average Diluted Shares Outstanding | 19.73% | 15.13% | 10.82% | 9.69% | 11.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |